بدائل البحث:
marked decrease » marked increase (توسيع البحث)
large decrease » larger decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
i large » ai large (توسيع البحث), _ large (توسيع البحث), b large (توسيع البحث)
a large » _ large (توسيع البحث)
marked decrease » marked increase (توسيع البحث)
large decrease » larger decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
i large » ai large (توسيع البحث), _ large (توسيع البحث), b large (توسيع البحث)
a large » _ large (توسيع البحث)
-
1
-
2
-
3
-
4
-
5
ECoG timescales decrease during spatial attention.
منشور في 2025"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"
-
6
<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"
منشور في 2025"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …"
-
7
-
8
-
9
-
10
Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients.
منشور في 2025"…<p><b>(A)</b> The geometric mean of the PSD was taken first across electrodes, and subsequently across patients, for the observed PSD (main graph) as well as for the aperiodic fit of the PSD (corresponding to a straight line under logarithmic scale for both <i>x</i> and <i>y</i> axes, inset graph). …"
-
11
-
12
-
13
-
14
-
15
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
منشور في 2025الموضوعات: -
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
منشور في 2025الموضوعات: -
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
منشور في 2025الموضوعات: -
18
-
19
-
20